Alzheimer’s disease represents one of the largest remaining unsolved threats to our health. This disease in common with other neurological disorders has been elusive because it is hard to diagnose. Our current ability to diagnose Alzheimer’s disease is...
NeoNeuro SAS and the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) group are pleased to announce that they have entered into a collaboration to validate the performance of the Aptamarker platform for Alzheimer's disease...
At the International level
“iPEPS-ICM” means “the incubator and nursery of enterprises Paris-Salpêtrière.” Eighteen months after it opened, the structure has become the first accelerator of innovation dedicated to diseases of the brain in France, and already hosts 15...